论文部分内容阅读
目的:探讨肝动脉化疗栓塞(THACE)联合~(32)磷内照射治疗原发性肝癌(PHC)的疗效及副作用。材料与方法:48例中晚期肝癌患者随机分为THACE+~(32)磷内照射治疗组(联合组,18例)和THACE组(栓塞组,30例),两组间年龄、性别、肿瘤直径及AFP比较无显著差异(P>0.05)。采用Seidinger插管,栓塞组注入阿霉素、丝裂霉素、5-氟尿啶啶及碘化油;联合组在此基础上再注入~(32)磷内照射。术后观察AFP、肿瘤大小、血象及肝功能等。结果:联合组完全缓解(CR)及部分缓解(PR)率达72.21％,栓塞组为46.66％,两组比较有显著差异(P<0.01):1年生存率分别为56.7％和30.6％(P<0.05)。两组治疗后血象均无明显改变,ALT升高较明显,但两组间无显著差异(P>0.05)。结论:THACE联合~(32)磷内照射治疗中晚期肝癌是一种新的有效的非手术疗法。
Objective: To investigate the efficacy and side effects of hepatic arterial chemoembolization (THACE) combined with internal irradiation with 32 P in the treatment of primary liver cancer (PHC). Materials and Methods: 48 cases of advanced hepatocellular carcinoma were randomly divided into THACE+32 (32) Intraphosphorin treatment group (combined group, 18 cases) and THACE group (embolization group, 30 cases). Age, sex, tumor diameter There was no significant difference between AFP and AFP (P>0.05). Seidinger cannula was used to inject doxorubicin, mitomycin, 5-fluorouracil, and iodized oil into the embolization group; the combined group was then injected with ~(32)phosphorus irradiation. Postoperatively, AFP, tumor size, hemogram and liver function were observed. Results: The complete remission (CR) and partial remission (PR) rates in the combined group were 72.21% and 46.66% in the embolization group. There was a significant difference between the two groups (P<0.01): 1-year survival rates were 56.7% and 30.6%, respectively ( P<0.05). There was no significant change in hemogram after treatment in both groups, but the ALT increased significantly, but there was no significant difference between the two groups (P>0.05). CONCLUSIONS: THACE combined with internal irradiation with 32 P is a new and effective non-surgical treatment for advanced liver cancer.